Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that Chief Operating Officer Jessica Morris will present at the ThinkEquity Conference on October 30, 2024, at 9:30 a.m. ET at the Mandarin Oriental, New York. The company is a fully-integrated biopharmaceutical firm focusing on pain management and public health solutions. Their key development includes TNX-102 SL for fibromyalgia, which has received FDA Fast Track designation. The company recently secured a contract with the U.S. DoD's DTRA worth up to $34 million for developing TNX-4200. Their commercial subsidiary, Tonix Medicines, markets Zembrace SymTouch and Tosymra for acute migraine treatment.
Tonix Pharmaceuticals (Nasdaq: TNXP) ha annunciato che il Direttore Operativo Jessica Morris presenterà alla ThinkEquity Conference il 30 ottobre 2024, alle 9:30 ora ET, presso il Mandarin Oriental di New York. L'azienda è una società biofarmaceutica completamente integrata, focalizzata sulla gestione del dolore e sulle soluzioni per la salute pubblica. Uno dei loro principali sviluppi include TNX-102 SL per la fibromialgia, che ha ottenuto la designazione Fast Track della FDA. Recentemente, l'azienda ha ottenuto un contratto con il DTRA del Dipartimento della Difesa degli Stati Uniti del valore di fino a 34 milioni di dollari per lo sviluppo di TNX-4200. La loro sussidiaria commerciale, Tonix Medicines, commercializza Zembrace SymTouch e Tosymra per il trattamento dell'emicrania acuta.
Tonix Pharmaceuticals (Nasdaq: TNXP) anunció que la Directora de Operaciones Jessica Morris presentará en la ThinkEquity Conference el 30 de octubre de 2024, a las 9:30 a.m. ET en el Mandarin Oriental de Nueva York. La compañía es una firma biofarmacéutica totalmente integrada, enfocada en el manejo del dolor y en soluciones de salud pública. Su desarrollo clave incluye TNX-102 SL para la fibromialgia, que ha recibido la designación Fast Track de la FDA. Recientemente, la empresa aseguró un contrato con la DTRA del Departamento de Defensa de EE. UU. por valor de hasta 34 millones de dólares para desarrollar TNX-4200. Su subsidiaria comercial, Tonix Medicines, comercializa Zembrace SymTouch y Tosymra para el tratamiento de la migraña aguda.
톤익스 제약사 (Nasdaq: TNXP)는 COO 제시카 모리스가 2024년 10월 30일 오전 9시 30분(동부 표준시) 뉴욕의 만다린 오리엔탈에서 씽크 이퀴티 컨퍼런스에 발표할 것이라고 발표했습니다. 이 회사는 통증 관리 및 공공 건강 솔루션에 집중하는 통합 바이오 제약 회사입니다. 그들의 주요 개발 제품 중 하나는 FDA 패스트 트랙 승인을 받은 섬유근육통 치료제 TNX-102 SL입니다. 최근 회사는 TNX-4200을 개발하기 위해 미국 국방부 DTRA와 최대 3,400만 달러의 계약을 체결했습니다. 그들의 상업 자회사인 톤익스 메디슨스는 급성 편두통 치료제로 제블레즙 심탐과 토시무라를 판매하고 있습니다.
Tonix Pharmaceuticals (Nasdaq: TNXP) a annoncé que la Directrice des opérations, Jessica Morris, présentera à la ThinkEquity Conference le 30 octobre 2024 à 9h30 (heure de l'Est) au Mandarin Oriental à New York. L'entreprise est une société biopharmaceutique entièrement intégrée, axée sur la gestion de la douleur et les solutions de santé publique. Leur développement phare inclut TNX-102 SL pour la fibromyalgie, qui a obtenu la désignation Fast Track de la FDA. Récemment, l'entreprise a sécurisé un contrat avec la DTRA du Département de la Défense des États-Unis d'une valeur allant jusqu'à 34 millions de dollars pour le développement de TNX-4200. Leur filiale commerciale, Tonix Medicines, commercialise Zembrace SymTouch et Tosymra pour le traitement des migraines aiguës.
Tonix Pharmaceuticals (Nasdaq: TNXP) gab bekannt, dass die Chief Operating Officer Jessica Morris am 30. Oktober 2024 um 9:30 Uhr ET auf der ThinkEquity Conference im Mandarin Oriental in New York präsentieren wird. Das Unternehmen ist eine voll integrierte bio-pharmazeutische Firma, die sich auf Schmerzmanagement und Lösungen für die öffentliche Gesundheit konzentriert. Eine ihrer Hauptentwicklungen ist TNX-102 SL für Fibromyalgie, das die Fast-Track-Designation der FDA erhalten hat. Das Unternehmen hat kürzlich einen Vertrag mit der DTRA des US-Verteidigungsministeriums im Wert von bis zu 34 Millionen Dollar zur Entwicklung von TNX-4200 gesichert. Ihre kommerzielle Tochtergesellschaft, Tonix Medicines, vertreibt Zembrace SymTouch und Tosymra zur Behandlung von akuten Migräneanfällen.
- None.
- None.
CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.
Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, and its priority is to progress TNX-102 SL, a product candidate for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institude of Drug Abuse and Addiction (NIDA). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182
Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505
Media Contact
Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432
FAQ
When is Tonix Pharmaceuticals (TNXP) presenting at the 2024 ThinkEquity Conference?
What is the status of Tonix Pharmaceuticals' (TNXP) TNX-102 SL development?
What recent contract did Tonix Pharmaceuticals (TNXP) secure with the Department of Defense?